Update on MDR Tuberculosis

Section 1: General
1. Impact of Higher Prevalence in Countries with Evolving Healthcare Systems and High Multidrug-resistant Tuberculosis Burden
2. How Multidrug-resistant Tuberculosis Poses a Major Challenge to Global TB Control Efforts?
3. Hotspots of Drug-resistant Tuberculosis as Key Drivers of Epidemic Intelligence for Public Health Action
4. Antibiotic Resistance Factors in Multidrug-resistant Tuberculosis
5. Trends in Multidrug-resistant Tuberculosis
6. Barriers in the Development of Specific Drug Susceptibility Testing
Section 2: Diagnostic
7. Decoding Resistance: Role of Mutations in Tuberculosis Treatment Failure
8. Early Detection Tools of Pulmonary Tuberculosis Affecting Treatment Outcome
9. How One Can Lead to Extensively Drug-resistant Tuberculosis?
10. Strain Typing Methods in the Identification of Drug Resistance in Mycobacterium Tuberculosis
11. Pattern and Characteristics of Mutation in Drug-resistant Clinical Isolates of Extrapulmonary Tuberculosis
12. Impact of Genome Sequencing on Multidrug-resistant Tuberculosis Diagnosis and Prevalence
13. Current Advances and Persistent Challenges in the Treatment of Pediatric Drug-resistant Tuberculosis
Section 3: Clinical
14. Closing the Gap between Evidence and Implementation in Multidrug-resistant Tuberculosis Management
15. Significance of Inappropriate or Interrupted Treatment in Tuberculosis
16. Nonadherence to Medication Regimens: Impact on Drug Resistance
17. Strategies to Prevent Mortality and Severe Illness in Multidrug-resistant Tuberculosis
18. Therapeutic Drugs Monitoring in Multidrug-resistant Treatment
Section 4: Treatment
19. Phytochemicals to Combat Multidrug-resistant Tuberculosis
20. Revolutionizing Drug-resistant Tuberculosis Care: The Global BPaL Implementation Experience
21. Poor Drug Quality: Impact on Drug Resistance
22. Surgical Modalities in Multidrug-resistant/Extensively Drug-resistant Tuberculosis
23. Recent Advances in Management of Drug-resistant Tuberculosis
24. Global Drug Pipeline for Tuberculosis Treatment
25. Current Regimens for Drug-resistant Tuberculosis
26. Challenges in Early Detection, Management and Prevention of Multidrug-resistant Tuberculosis in Geriatric Patients
Section 5: Associated Diseases
27. Multidrug-resistant Tuberculosis during Pregnancy
28. Molecular Changes in Diabetes and Multidrug-resistant Tuberculosis
29. Psychiatric Disorders in Drug-resistant Tuberculosis
30. Antimicrobial Resistance Fight: Preventing Drug Resistance
31. Mitigating Strategies to Prevent Drug Resistance
32. Airborne Transmission of Drug-resistant Tuberculosis
33. Problematic Issues in Implementation of Drug-resistant Tuberculosis Case Management
Section 6: Prevention
34. Multidrug Resistance in Tuberculosis: Contact Tracing and Isolation of Infected Individuals
35. Multidrug-resistant Tuberculosis: Infection Prevention and Control Measures in Healthcare Settings
36. Importance of Prevention, Early Diagnosis and Adherence to Treatment: Latent and Subclinical TB
37. Novel Tuberculosis Vaccines: A Promising Approach for Multidrug-resistant Tuberculosis Elimination
Section 7: Newer Initiatives
38. Role of Artificial Intelligence in Tuberculosis
39. Artificial Intelligence in Managing Drug Adherence
40. Role of DNA Fingerprinting in Multidrug-resistant Tuberculosis
41. Epigenetic Regulation of Drug Resistance in Tuberculosis
42. Functional Analysis of Toxin-antitoxin System in Multidrug-resistant Tuberculosis
43. Phenotypic Drug Resistance: An Update in Pediatric Tuberculosis

VK Arora Diploma in Chest Diseases (DCD) MD (Tuberculosis and Respiratory Diseases/Medicine) MBBS
Tuberculous and Chest Diseases Specialist; Chairman, TB Association of India; Executive Editor of Indian Journal of Tuberculosis, New Delhi, India
Kamal Chopra MBBS MD (Chest and TB) DTCE (Diploma in TB Control and Eradication) Tokyo
Consultant and Former Director, New Delhi Tuberculosis Centre; Academic Editor, PLoS One; Associate Executive Editor of Indian Journal of Tuberculosis, New Delhi, India